Table 1—

Baseline and on-treatment characteristics of randomized subjects

All subjects
Primary prevention
Secondary prevention
AtorvastatinPlaceboAtorvastatinPlaceboAtorvastatinPlacebo
n1,2111,199959946252253
Age (years)61.1 ± 8.161.0 ± 8.260.5 ± 8.360.4 ± 8.363.1 ± 7.263.2 ± 7.4
    ≥65448 (37)422 (35)332 (35)305 (32)116 (46)117 (46)
Men796 (66)803 (67)593 (62)594 (63)203 (81)209 (83)
Race
    Caucasian1,018 (84)1,011 (84)805 (84)792 (84)213 (85)219 (87)
    Black81 (6.7)74 (6.2)73 (7.6)68 (7.2)8 (3.2)6 (2.4)
BMI (kg/m2)28.9 ± 3.728.8 ± 3.828.9 ± 3.728.8 ± 3.728.9 ± 3.728.9 ± 3.8
Current smokers147 (12)153 (13)119 (12)132 (14)28 (11)21 (8)
Median duration of diabetes (years)8.08.08.08.08.010.0
Blood pressure (mmHg)
    Systolic133.1 ± 16.8133.4 ± 16.4133.0 ± 17.0133.0 ± 16.7133.6 ± 16.0134.9 ± 15.3
    Diastolic76.9 ± 9.176.3 ± 9.077.1 ± 8.876.7 ± 8.876.0 ± 10.074.9 ± 9.6
History of hypertension671 (55)657 (55)498 (52)499 (53)173 (69)158 (63)
History of hyperlipidemia343 (28)369 (31)265 (28)275 (29)78 (31)94 (37)
Glomerular filtration rate (ml/min per 1.73 m2)65.7 ± 11.565.8 ± 11.966.1 ± 11.466.7 ± 11.864.0 ± 11.662.6 ± 11.9
CVD history
    Myocardial infarction208 (17)187 (16)00208 (83)187 (74)
    Interventional procedure145 (12)170 (14)00145 (58)170 (67)
    Angina200 (17)195 (16)55 (6)47 (5)145 (58)148 (58)
    Peripheral arterial disease101 (8)107 (9)64 (7)53 (6)37 (15)54 (21)
    Cerebrovascular disease61 (5)62 (5)38 (4)32 (3)23 (9)30 (12)
    Arrhythmia108 (9)119 (10)67 (7)77 (8)41 (16)42 (17)
LDL cholesterol (mg/dl)
    Baseline113 ± 25114 ± 26114 ± 26114 ± 26112 ± 24113 ± 25
    End of treatment (% change)−30.29−1.09−30.48−0.48−29.65−3.31
    P value (% change)<0.0001<0.0001<0.0001
Total cholesterol (mg/dl)
    Baseline194 ± 31194 ± 31195 ± 31195 ± 31188 ± 26191 ± 29
    End of treatment (% change)−19.70−1.41−19.78−1.38−19.47−1.45
    P value (% change)<0.0001<0.0001<0.0001
HDL cholesterol (mg/dl)
    Baseline47 ± 1447 ± 1348 ± 1447 ± 1342 ± 1144 ± 12
    End of treatment (% change)2.17−0.181.93−0.332.980.52
    P value (% change)0.00050.0020.143
Triglycerides (mg/dl)
    Baseline147 (101–208)145 (102–213)145 (99–205)144.5 (103–211)151.5 (104–219)147 (99–219)
    End of treatment (% change)−3.9010.01−4.727.24−0.7920.44
    P value (% change)<0.0001<0.00010.0005
A1C (%)7.6 ± 1.27.5 ± 1.37.6 ± 1.27.6 ± 1.37.6 ± 1.37.4 ± 1.2
    Baseline7.8 ± 1.47.7 ± 1.47.8 ± 1.47.7 ± 1.47.9 ± 1.57.8 ± 1.4
    End of treatment
  • Data are means ± SD, n (%), mean, or median (interquartile range). End of treatment lipid changes are from a last-observation-carried-forward analysis. To convert from mg/dl to mmol/l for cholesterol, divide by 38.67; for triglycerides, divide by 88.57.